Skip to main content
Erschienen in:

01.05.2005 | Leitthema

Impfstrategien zur Prävention oder Therapie von Tumoren

verfasst von: C. M. Britten, PD Dr. U. Sahin

Erschienen in: Die Onkologie | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Tumoren unterscheiden sich molekular von dem Gewebe, aus dem sie sich entwickeln, und können dadurch von Zellen des Immunsystems selektiv erkannt und zerstört werden. Die Identifikation einer großen Zahl von Antigenen, die ausschließlich oder präferenziell in Tumorzellen nachweisbar sind, bildet die molekulare Grundlage, auf der sich moderne Impfstrategien zur Prävention und Therapie von Krebserkrankungen entwickelt haben. Der vorliegende Artikel diskutiert die in den letzten Jahren in klinischen Studien zum Einsatz gekommenen Strategien und fasst den aktuellen Stand ihrer klinischen Prüfung zusammen. Hervorgehoben wird auch die Bedeutung von Surrogatmarkern zur immunologischen Erfolgskontrolle von Impfprotokollen.
Literatur
1.
Zurück zum Zitat Coley WB (1896) Further observations upon treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp 7:157–162 Coley WB (1896) Further observations upon treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp 7:157–162
2.
Zurück zum Zitat Gross L (1943) Intradermal immunization of C3H mice against sarcoma that originated in an animal of the same line. Cancer Res 3:326–333 Gross L (1943) Intradermal immunization of C3H mice against sarcoma that originated in an animal of the same line. Cancer Res 3:326–333
3.
Zurück zum Zitat Klein G, Sjorgen H, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561–1572 Klein G, Sjorgen H, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561–1572
4.
Zurück zum Zitat Rouse BT, Wagner H, Harris AW (1972) In vivo activity of in vitro iimunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes. J Immunol 108:1353–1361 Rouse BT, Wagner H, Harris AW (1972) In vivo activity of in vitro iimunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes. J Immunol 108:1353–1361
5.
Zurück zum Zitat van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den EB, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647 van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den EB, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647
6.
Zurück zum Zitat De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora JP, Wolfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum-)variants of mouse tumor P815: cloning of the gene of tum-antigen P9l A and identification of the tum-mutation. Proc Natl Acad Sci USA 85:2274–2278 De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora JP, Wolfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum-)variants of mouse tumor P815: cloning of the gene of tum-antigen P9l A and identification of the tum-mutation. Proc Natl Acad Sci USA 85:2274–2278
7.
Zurück zum Zitat Türeci G, Usener D, Schneider S, Sahin U (2005) Identification of tumor-associated autoantigens with SEREX. Methods Mol Med 109:137–154 Türeci G, Usener D, Schneider S, Sahin U (2005) Identification of tumor-associated autoantigens with SEREX. Methods Mol Med 109:137–154
8.
Zurück zum Zitat Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810–11813 Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810–11813
9.
Zurück zum Zitat Vainio H (2002) The need for preventive drugs and vaccines in global cancer control: a challenge for public health and for industry. Toxicol Ind Health 18:84–90 Vainio H (2002) The need for preventive drugs and vaccines in global cancer control: a challenge for public health and for industry. Toxicol Ind Health 18:84–90
10.
Zurück zum Zitat Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765 Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765
11.
Zurück zum Zitat Forni G, Curcio C, Spadaro M, Iliffe J, Quaglino E, Di Carlo E, Musiani P Lollini PL (2003) Immunization in tumor prevention. Int Immunopharmacol 3:1151–1158 Forni G, Curcio C, Spadaro M, Iliffe J, Quaglino E, Di Carlo E, Musiani P Lollini PL (2003) Immunization in tumor prevention. Int Immunopharmacol 3:1151–1158
12.
Zurück zum Zitat Sabel MS, Sondak VK (2002) Tumor vaccines: a role in preventing recurrence in melanoma? Am J Clin Dermatol 3:609–616 Sabel MS, Sondak VK (2002) Tumor vaccines: a role in preventing recurrence in melanoma? Am J Clin Dermatol 3:609–616
13.
Zurück zum Zitat Mocellin S, Mandruzzato S, Bronte V, Lise M, and Nitti D (2004) Part I: Vaccines for solid tumours. Lancet Oncol 5:681–689 Mocellin S, Mandruzzato S, Bronte V, Lise M, and Nitti D (2004) Part I: Vaccines for solid tumours. Lancet Oncol 5:681–689
14.
Zurück zum Zitat Nawrocki S, Murawa P, Malicki J, Kapcinska M, Gryska K, Izycki D, Kaczmarek A, Laciak M, Czapczyk A, Karczewska A, Rose-John S, Mackiewicz A (2000) Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 74:81–86 Nawrocki S, Murawa P, Malicki J, Kapcinska M, Gryska K, Izycki D, Kaczmarek A, Laciak M, Czapczyk A, Karczewska A, Rose-John S, Mackiewicz A (2000) Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 74:81–86
15.
Zurück zum Zitat Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599 Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599
16.
Zurück zum Zitat Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MGJr, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350 Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MGJr, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350
17.
Zurück zum Zitat Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19:2576–2582 Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19:2576–2582
18.
Zurück zum Zitat Baars A, Claessen AM, Wagstaff J, Giaccone G, Scheper RJ, Meijer S, Schakel MJ, Gall HE, Meijer CJ, Vermorken JB, Pinedo HM, and van den Eertwegh AJ (2002) A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:1230–1234 Baars A, Claessen AM, Wagstaff J, Giaccone G, Scheper RJ, Meijer S, Schakel MJ, Gall HE, Meijer CJ, Vermorken JB, Pinedo HM, and van den Eertwegh AJ (2002) A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:1230–1234
19.
Zurück zum Zitat Castelli C, Rivoltini L, Rini F, Belli F, Testori A, Maio M, Mazzaferro V, Coppa J, Srivastava PK, Parmiani G (2004) Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 53:227–233 Castelli C, Rivoltini L, Rini F, Belli F, Testori A, Maio M, Mazzaferro V, Coppa J, Srivastava PK, Parmiani G (2004) Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 53:227–233
20.
Zurück zum Zitat Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395–425; Epub 2001:395–425 Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395–425; Epub 2001:395–425
21.
Zurück zum Zitat Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchiano A, Andreola S, Camerini R, Corsi M, Lewis JJ, Srivastava PK, Parmiani G (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9:3235–3245 Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchiano A, Andreola S, Camerini R, Corsi M, Lewis JJ, Srivastava PK, Parmiani G (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9:3235–3245
22.
Zurück zum Zitat Belli F, Testori A, Rivoltini L et al. (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180 Belli F, Testori A, Rivoltini L et al. (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180
23.
Zurück zum Zitat Sullenger BA, Gilboa E (2002) Emerging clinical applications of RNA. Nature 418:252–258 Sullenger BA, Gilboa E (2002) Emerging clinical applications of RNA. Nature 418:252–258
24.
Zurück zum Zitat Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60:1028–034 Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60:1028–034
25.
Zurück zum Zitat Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263 Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263
26.
Zurück zum Zitat Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401–411 Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401–411
27.
Zurück zum Zitat Boon T, Coulie PG, Van den EB (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268 Boon T, Coulie PG, Van den EB (1997) Tumor antigens recognized by T cells. Immunol Today 18:267–268
28.
Zurück zum Zitat Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Muntefering H, Huber C, Sahin U, Tureci O (2004) Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res 64:5988–5993 Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Muntefering H, Huber C, Sahin U, Tureci O (2004) Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res 64:5988–5993
29.
Zurück zum Zitat Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1 Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1
30.
Zurück zum Zitat Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458 Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458
31.
Zurück zum Zitat Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Jnt J Cancer 86:385–392 Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Jnt J Cancer 86:385–392
32.
Zurück zum Zitat Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697–10702 Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697–10702
33.
Zurück zum Zitat Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760–4765 Jäger E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jäger D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760–4765
34.
Zurück zum Zitat Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284 Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284
35.
Zurück zum Zitat Oka Y, Tsuboi A., Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H (2004) Induction of WT1 (Wilms‘ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101:13885–13890 Oka Y, Tsuboi A., Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H (2004) Induction of WT1 (Wilms‘ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101:13885–13890
36.
Zurück zum Zitat Disis ML, Schiffman K, Salazar LG, Almand B, Knutson KL (2003) HER-2/neu vaccines. Cancer Chemother Biol Response Modif 21:275–285 Disis ML, Schiffman K, Salazar LG, Almand B, Knutson KL (2003) HER-2/neu vaccines. Cancer Chemother Biol Response Modif 21:275–285
37.
Zurück zum Zitat Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293 Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293
38.
Zurück zum Zitat Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 [Suppl 2]:14567–14571 Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 [Suppl 2]:14567–14571
39.
Zurück zum Zitat Essajee S, Kaufman HL (2004) Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 4:575–588 Essajee S, Kaufman HL (2004) Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 4:575–588
40.
Zurück zum Zitat Hodge JW, McLaughlin JP, Kantor JA, Schlom J (1997) Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15:759–768 Hodge JW, McLaughlin JP, Kantor JA, Schlom J (1997) Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15:759–768
41.
Zurück zum Zitat Boisgerault F, Moron G, Leclerc C (2002) Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 1:101–109 Boisgerault F, Moron G, Leclerc C (2002) Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 1:101–109
42.
Zurück zum Zitat Jäger E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LT, Knuth A (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198–12203 Jäger E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LT, Knuth A (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198–12203
43.
Zurück zum Zitat Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995 Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995
44.
Zurück zum Zitat Puccetti P, Bianchi R, Fioretti MC, Ayroldi E, Uyttenhove C, Van Pel A, Boon T, Grohmann U (1994) Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur J Immunol 24:1446–1452 Puccetti P, Bianchi R, Fioretti MC, Ayroldi E, Uyttenhove C, Van Pel A, Boon T, Grohmann U (1994) Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur J Immunol 24:1446–1452
45.
Zurück zum Zitat Yee C, Greenberg P (2002) Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2:409–419 Yee C, Greenberg P (2002) Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2:409–419
46.
Zurück zum Zitat Pittet MJ, Speiser DE, Valmori D, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P (2001) Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmaco 1:1235–1247 Pittet MJ, Speiser DE, Valmori D, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P (2001) Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmaco 1:1235–1247
47.
Zurück zum Zitat Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P (2004) Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 27:298–308 Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P (2004) Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 27:298–308
48.
Zurück zum Zitat Coulie PG, van der BP (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131–137 Coulie PG, van der BP (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol 15:131–137
Metadaten
Titel
Impfstrategien zur Prävention oder Therapie von Tumoren
verfasst von
C. M. Britten
PD Dr. U. Sahin
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0865-x

Weitere Artikel der Ausgabe 5/2005

Der Onkologe 5/2005 Zur Ausgabe

Weiterbildung · Zertifizierte Fortbildung

Nierenzellkarzinom

Neu im Fachgebiet Onkologie

Tisotumab-Vedotin verlängert Überleben nach Zervixkarzinom-Rezidiv

13.07.2024 Zervixkarzinom Nachrichten

Für Frauen mit rezidiviertem oder metastasiertem Zervixkarzinom und Versagen der Erstlinientherapie zeichnet sich eine Verbesserung der Behandlungsoptionen ab: Mit dem Antikörper-Wirkstoff-Konjugat Tisotumab-Vedotin überleben sie zwei Monate länger als mit einer Chemotherapie.

Was das Überwachen von Risikopersonen für Pankreaskrebs bringt

12.07.2024 Pankreaskarzinom Nachrichten

Programme zur Überwachung von Hochrisikokandidaten für duktales Adenokarzinom des Pankreas führen womöglich zu früherer Diagnose. Ob sich das auch in einem Überlebensvorteil niederschlägt, hat eine Studie getestet.

Prostatakarzinome der ISUP-Gruppe 1 nicht immer harmlos

11.07.2024 Prostatakarzinom Nachrichten

Nicht bei allen Prostatakarzinomen der Gleason-Graduierungsgruppe 1 kann man davon ausgehen, dass sie benigne sind. In einer Studie aus dem UKE Hamburg hatten auch in dieser Gruppe bestimmte Patienten ein deutlich erhöhtes Risiko für einen ungünstigen Verlauf.

Taugen Risikoscores für Schlaganfall und Blutungen auch bei Krebskranken?

Britische Registerdaten sprechen dafür, dass sich die Blutungsrisikoprädiktion bei Personen mit Vorhofflimmern, die zugleich an Krebs leiden, nicht einfach aus Kohorten ohne Krebs übertragen lässt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.